- Founders enter & conduct due diligence within the pharmaceutical Alt-Therapies market
- Initial introduction for the company mission with Key Opinion Leaders (KOLs) and pharmaceutical executives in the pain and CNS specialties
- Verséa Holdings, Inc. was formed after founders exited a public sale in the medical space
- Core executive leadership team expands to 6 and founders capital vested.
- Verséa Wellness brand launch at medical conference
- Medical Director and Physician Advisors Sign On
- Soft launch of company & products at medical conferences
- Completes 2 IRB studies accepted for medical publication
- Verséa Wellness products hit the direct to clinician market nationwide
- Clinical and regulatory experts join
- Core management team expands to 9
- Medical advisory team to 14
- Verséa Diagnostics division formed
- Verséa Diagnostics POC & OTC products available nationwide
- Verséa releases its own customized software solution to help manage: products, sales, distribution for master distributors, hcps and consumers with ordering and fulfillment.
- 4+ NIH grant submissions
- Operations expansion globally into EAU and FDA Diagnostics
- Versea aligns with expanded customer base to include urgent care groups, major hospitals and surgery centers (ASC’s) nationally
- 25+ medical doctors sign MSA and take on clinical and commercial advisory roles
- GPO’s, Ex US expansion, Telehealth & large partnerships executed for scalability
- Verséa and its research partner, VitaMed Research, achieves 1st in the United States HIPPA Compliant IRB Approved, Patient Registry.
- Research study quickly enrolls 300+ Patients completing INH survey month to month on Verséa products
- Verséa secures partnerships with leading manufacturers of point of care diagnostics
Team Expansion: Management and Medical Advisory teams expand
New Business Divisions: Biologics, Discovery